We have used the KRASG12C inhibitors to explore the effects of KRASG12C activation in tumor models and identified three key cellular processes activated by mutant KRAS, effective inhibition of which requires inhibition of both PI3K/mTOR and ERK signaling: Cyclin D1 expression, cell survival, and cap-dependent translation. Here, KRAS is linked to neoplasm.